» Articles » PMID: 25613668

TM-233, a Novel Analog of 1'-acetoxychavicol Acetate, Induces Cell Death in Myeloma Cells by Inhibiting Both JAK/STAT and Proteasome Activities

Overview
Journal Cancer Sci
Specialty Oncology
Date 2015 Jan 24
PMID 25613668
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Although the introduction of bortezomib and immunomodulatory drugs has led to improved outcomes in patients with multiple myeloma, the disease remains incurable. In an effort to identify more potent and well-tolerated agents for myeloma, we have previously reported that 1'-acetoxychavicol acetate (ACA), a natural condiment from South-East Asia, induces apoptotic cell death of myeloma cells in vitro and in vivo through inhibition of NF-κB-related functions. Searching for more potent NF-κB inhibitors, we developed several ACA analogs based on quantitative structure-activity relationship analysis. TM-233, one of these ACA analogs, inhibited cellular proliferation and induced cell death in various myeloma cell lines with a lower IC50 than ACA. Treatment with TM-233 inhibited constitutive activation of JAK2 and STAT3, and then downregulated the expression of anti-apoptotic Mcl-1 protein, but not Bcl-2 and Bcl-xL proteins. In addition, TM-233 rapidly decreased the nuclear expression of NF-κB and also decreased the accumulation of cytosolic NF-κB. We also examined the effects of TM-233 on bortezomib-resistant myeloma cells that we recently established, KMS-11/BTZ and OPM-2/BTZ. TM-233, but not bortezomib, inhibited cellular proliferation and induced cell death in KMS-11/BTZ and OPM-2/BTZ cells. Interestingly, the combination of TM-233 and bortezomib significantly induced cell death in these bortezomib-resistant myeloma cells through inhibition of NF-κB activity. These results indicate that TM-233 could overcome bortezomib resistance in myeloma cells mediated through different mechanisms, possibly inhibiting the JAK/STAT pathway. In conclusion, TM-233 might be a more potent NF-κB inhibitor than ACA, and could overcome bortezomib resistance in myeloma cells.

Citing Articles

Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers.

Li B, Wan Q, Li Z, Chng W Cancers (Basel). 2021; 13(20).

PMID: 34680295 PMC: 8533975. DOI: 10.3390/cancers13205147.


Multiple Myeloma Inhibitory Activity of Plant Natural Products.

Johrer K, iek S Cancers (Basel). 2021; 13(11).

PMID: 34072312 PMC: 8198565. DOI: 10.3390/cancers13112678.


The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.

Paul B, Zhao Y, Loitsch G, Feinberg D, Mathews P, Barak I Cancer Med. 2020; 9(16):5869-5880.

PMID: 32628819 PMC: 7433821. DOI: 10.1002/cam4.3265.


Targeting MCL-1 in hematologic malignancies: Rationale and progress.

Wei A, Roberts A, Spencer A, Rosenberg A, Siegel D, Walter R Blood Rev. 2020; 44:100672.

PMID: 32204955 PMC: 7442684. DOI: 10.1016/j.blre.2020.100672.


Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.

Fu Y, Liu X, Zhang F, Jiang S, Liu J, Luo Y Cell Death Dis. 2019; 10(4):319.

PMID: 30967527 PMC: 6456577. DOI: 10.1038/s41419-019-1551-z.


References
1.
Murakami A, Ohigashi H, Koshimizu K . Possible anti-tumour promoting properties of traditional Thai food items and some of their active constituents. Asia Pac J Clin Nutr. 2013; 3(4):185-91. View

2.
Palumbo A, Anderson K . Multiple myeloma. N Engl J Med. 2011; 364(11):1046-60. DOI: 10.1056/NEJMra1011442. View

3.
Jager S, Groll M, Huber R, Wolf D, Heinemeyer W . Proteasome beta-type subunits: unequal roles of propeptides in core particle maturation and a hierarchy of active site function. J Mol Biol. 1999; 291(4):997-1013. DOI: 10.1006/jmbi.1999.2995. View

4.
Liu H, Westergard T, Cashen A, Piwnica-Worms D, Kunkle L, Vij R . Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4. Cancer Cell. 2014; 25(4):530-42. PMC: 4097146. DOI: 10.1016/j.ccr.2014.03.008. View

5.
Wang J, Hendrix A, Hernot S, Lemaire M, de Bruyne E, Van Valckenborgh E . Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014; 124(4):555-66. DOI: 10.1182/blood-2014-03-562439. View